Activation of D1R/PKA/Mtor Signaling Cascade in Medial
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Comprehensive Review on the Interaction Between Natural Compounds and Brain Receptors: Benefits and Toxicity
European Journal of Medicinal Chemistry 174 (2019) 87e115 Contents lists available at ScienceDirect European Journal of Medicinal Chemistry journal homepage: http://www.elsevier.com/locate/ejmech Review article Comprehensive review on the interaction between natural compounds and brain receptors: Benefits and toxicity * Ana R. Silva a, Clara Grosso b, , Cristina Delerue-Matos b,Joao~ M. Rocha a, c a Centre of Molecular and Environmental Biology (CBMA), Department of Biology (DB), University of Minho (UM), Campus Gualtar, P-4710-057, Braga, Portugal b REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Politecnico do Porto, Rua Dr. Antonio Bernardino de Almeida, 431, P-4249-015, Porto, Portugal c REQUIMTE/LAQV, Grupo de investigaçao~ de Química Organica^ Aplicada (QUINOA), Laboratorio de polifenois alimentares, Departamento de Química e Bioquímica (DQB), Faculdade de Ci^encias da Universidade do Porto (FCUP), Rua do Campo Alegre, s/n, P-4169-007, Porto, Portugal article info abstract Article history: Given their therapeutic activity, natural products have been used in traditional medicines throughout the Received 6 December 2018 centuries. The growing interest of the scientific community in phytopharmaceuticals, and more recently Received in revised form in marine products, has resulted in a significant number of research efforts towards understanding their 10 April 2019 effect in the treatment of neurodegenerative diseases, such as Alzheimer's (AD), Parkinson (PD) and Accepted 11 April 2019 Huntington (HD). Several studies have shown that many of the primary and secondary metabolites of Available online 17 April 2019 plants, marine organisms and others, have high affinities for various brain receptors and may play a crucial role in the treatment of diseases affecting the central nervous system (CNS) in mammalians. -
NIDA Drug Supply Program Catalog, 25Th Edition
RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25 -
Implications of Dopamine D3 Receptor for Glaucoma: In-Silico and In-Vivo Studies
International PhD Program in Neuropharmacology XXVI Cycle Implications of dopamine D3 receptor for glaucoma: in-silico and in-vivo studies PhD thesis Chiara Bianca Maria Platania Coordinator: Prof. Salvatore Salomone Tutor: Prof. Claudio Bucolo Department of Clinical and Molecular Biomedicine Section of Pharmacology and Biochemistry. University of Catania - Medical School December 2013 Copyright ©: Chiara B. M. Platania - December 2013 2 TABLE OF CONTENTS ACKNOWLEDGEMENTS............................................................................ 4 LIST OF ABBREVIATIONS ........................................................................ 5 ABSTRACT ................................................................................................... 7 GLAUCOMA ................................................................................................ 9 Aqueous humor dynamics .................................................................. 10 Pharmacological treatments of glaucoma............................................ 12 Pharmacological perspectives in treatment of glaucoma ..................... 14 Animal models of glaucoma ............................................................... 18 G PROTEIN COUPLED RECEPTORS ....................................................... 21 GPCRs functions and structure ........................................................... 22 Molecular modeling of GPCRs ........................................................... 25 D2-like receptors ............................................................................... -
Handbook of Schizophrenia Spectrum Disorders, Volume III
Handbook of Schizophrenia Spectrum Disorders, Volume III Michael S. Ritsner Editor Handbook of Schizophrenia Spectrum Disorders, Volume III Therapeutic Approaches, Comorbidity, and Outcomes 123 Editor Michael S. Ritsner Technion – Israel Institute of Technology Rappaport Faculty of Medicine Haifa Israel [email protected] ISBN 978-94-007-0833-4 e-ISBN 978-94-007-0834-1 DOI 10.1007/978-94-007-0834-1 Springer Dordrecht Heidelberg London New York Library of Congress Control Number: 2011924745 © Springer Science+Business Media B.V. 2011 No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Foreword Schizophrenia Spectrum Disorders: Insights from Views Across 100 years Schizophrenia spectrum and related disorders such as schizoaffective and mood dis- orders, schizophreniform disorders, brief psychotic disorders, delusional and shared psychotic disorders, and personality (i.e., schizotypal, paranoid, and schizoid per- sonality) disorders are the most debilitating forms of mental illness, worldwide. There are 89,377 citations (including 10,760 reviews) related to “schizophrenia” and 2118 (including 296 reviews) related to “schizophrenia spectrum” in PubMed (accessed on August 12, 2010). The classification of these disorders, in particular, of schizophrenia, schizoaf- fective and mood disorders (referred to as functional psychoses), has been debated for decades, and its validity remains controversial. -
Guidelines for Biological Treatment of Schizophrenia, Part 2
The World Journal of Biological Psychiatry, 2013; 14: 2–44 GUIDELINES World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects ALKOMIET HASAN 1 , PETER FALKAI1 , THOMAS WOBROCK 2 , JEFFREY LIEBERMAN 3 , BIRTE GLENTHOJ 4 , WAGNER F. GATTAZ 5 , FLORENCE THIBAUT6 & HANS-JÜ RGEN M Ö LLER 1 , WFSBP Task force on Treatment Guidelines for Schizophrenia * 1 Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany, 2 Centre of Mental Health, Darmstadt-Dieburg Clinics, Darmstadt, Germany, 3 Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, Lieber Center for Schizophrenia Research, New York, USA, 4 Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Copenhagen University Hospital, Psychiatric Center Glostrup, Denmark, 5 Department of Psychiatry, University of Sao Paulo, Brazil, and 6 University Hospital Ch. Nicolle, Faculty of Medicine, INSERM, Rouen, France Abstract These updated guidelines are based on a fi rst edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence- based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifi cally meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the fi rst version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. -
Serotonergic System Modulation Holds Promise for L‐Dopa‐Induced Dyskinesias in Hemiparkinsonian Rats: a Systematic Review
EXCLI Journal 2020;19:268-295 – ISSN 1611-2156 Received: January 03, 2020, accepted: February 24, 2020, published: March 02, 2020 Review article: SEROTONERGIC SYSTEM MODULATION HOLDS PROMISE FOR L‐DOPA‐INDUCED DYSKINESIAS IN HEMIPARKINSONIAN RATS: A SYSTEMATIC REVIEW Fereshteh Farajdokht1, 2, Saeed Sadigh-Eteghad2, Alireza Majdi2, Fariba Pashazadeh1,3, Seyyed Mehdi Vatandoust2, Mojtaba Ziaee4,5, Fatemeh Safari6, Pouran Karimi2, Javad Mahmoudi2* 1 Research Center for Evidence-Based Medicine (EBM), Health Management and Safety Promotion Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran 2 Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran 3 Iranian Evidence-Based Medicine (EBM) Center, a Joanna Briggs Institute Affiliated Group 4 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 5 Phytopharmacology Research Center, Maragheh University of Medical Sciences, Maragheh, Iran 6 Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran * Corresponding author: Dr. Javad Mahmoudi, Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran, Postal code: 5166614756, Iran, Tel: +984133351284, E-mails: [email protected], [email protected] http://dx.doi.org/10.17179/excli2020-1024 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/). ABSTRACT The alleged effects of serotonergic agents in alleviating levodopa-induced dyskinesias (LIDs) in parkinsonian patients are debatable. To this end, we systematically reviewed the serotonergic agents used for the treatment of LIDs in a 6-hydroxydopamine model of Parkinson’s disease in rats. We searched MEDLINE via PubMed, Embase, Google Scholar, and Proquest for entries no later than March 2018, and restricted the search to publications on serotonergic agents used for the treatment of LIDs in hemiparkinsonian rats. -
A 1A9, A431 and A549 Cell Lines, 3478 12Α,13Α-Aziridinyl Epothilone
Index A Acanthoscelides obtectus, 4091 1A9, A431 and A549 cell lines, 3478 Acanthostrongylophora, 1293 12a,13a-Aziridinyl epothilone derivatives, 990 Acari, 4070, 4083 Aaptos ciliata, 1292 Acaricides, 4070, 4076, 4083 AATs. See Anthocyanin acyltransferases Accelerated solvent extraction (ASE), 1017, (AATs) 2017, 2021–2023, 2032, 2037, 2111 Ab (1-42), 2287 p-Acceptors, 692 ABA biosynthesis, 1736 Accretion, 2405 Ab aggregation, 2286 Accumulation, 2321 Abdominal troubles, 3477 Acetaldehyde (ATL), 2902 Aberrant behavior, 1375 Acetaldehyde acid, 1783 Aberrant estrous cycles, 2421 Acetate, 50, 59 Abies alba, 2980 Acetate-mevalonate (Ac-MEV), 2943 Abietadiene synthase, 2725 Acetate pathway, 2314 Abiotic and biotic elicitors, 2783 Acetic acid (ACE), 851, 1608, 2884 Abiotic factor, 1697 Acetogenic bacteria, 2443 Abiotic stresses, 2930 Acetone, 3371 Ab neuropathology, 2285 Acetonitrile, 691, 1170, 1175 Ab oligomerization, 2285 3-Acetylaconitine, 1508 Ab oligomers, 2283 Acetyl-ACP, 963 Ab peptides, 1308, 2285 Acetyl-and butyrylcholinesterase inhibitors, Ab polymerization, 2287 3488 Abrin, 296 Acetylcholine (ACh), 1241, 1306, 1333, 1526, Abscisic acid (ABA), 2860, 3591 1527, 1529, 1530, 3710 Absolute configuration, 930, 3320 Acetylcholine esterase, 51, 52 Absolute configuration of monosaccharides, Acetylcholine esterase inhibitor activity, 2906 3319 Acetylcholinesterase (AChE), 41, 1246, 1308, Absorbance (A), 3334, 3380 1334, 1527, 1529–1533, 1535, 4097 Absorbance spectrum, 3929, 3933, 3934 Acetyl-CoA, 61, 584 Absorption, 1230, 2321, 2470–2476, Acetyl-CoA carboxylase (ACC), 1658, 1825 2478–2481, 3134, 3377, 3616, 4024 3-Acetyldeoxynivalenol, 3127, 3145 coefficient, 3380 15-Acetyl deoxynivalenol (15ADON), and metabolism, 1428 3127, 3145 wavelength, 4028 Acetylerucifoline, 1061 Abusive correlations, 2410 Acetylgaertneroside, 3054 Acacetin, 1830 60-O-Acetylgeniposide, 3058 Acacia, 865 8-O-Acetylharpagide, 3055 a2C adrenergic, 4124 Acetylintermedine, 1061 Acanthaceae, 801 Acetyllycopsamine, 1061 K.G. -
Download Date 02/10/2021 14:22:57
Exploration of cognitive and neurochemical deficits in an animal model of schizophrenia. Investigation into sub-chronic PCP-induced cognitive deficits using behavioural, neurochemical and electrophysiological techniques; and use of receptor-selective agents to study the pharmacology of antipsychotics in female rats. Item Type Thesis Authors McLean, Samantha L. Rights <a rel="license" href="http://creativecommons.org/licenses/ by-nc-nd/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by- nc-nd/3.0/88x31.png" /></a><br />The University of Bradford theses are licenced under a <a rel="license" href="http:// creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Licence</a>. Download date 02/10/2021 14:22:57 Link to Item http://hdl.handle.net/10454/4451 University of Bradford eThesis This thesis is hosted in Bradford Scholars – The University of Bradford Open Access repository. Visit the repository for full metadata or to contact the repository team © University of Bradford. This work is licenced for reuse under a Creative Commons Licence. EXPLORATION OF COGNITIVE AND NEUROCHEMICAL DEFICITS IN AN ANIMAL MODEL OF SCHIZOPHRENIA Investigation into sub-chronic PCP-induced cognitive deficits using behavioural, neurochemical and electrophysiological techniques; and use of receptor-selective agents to study the pharmacology of antipsychotics in female rats Samantha Louise MCLEAN submitted for the degree of Doctor of Philosophy School of Pharmacy University of Bradford 2010 i ABSTRACT Keywords: Rat; Phencyclidine; Antipsychotics; Cognition; Dopamine; 5-HT; GABA Cognitive dysfunction is a core characteristic of schizophrenia, which can often persist when other symptoms, particularly positive symptoms, may be improved with drug treatment. -
New Information of Dopaminergic Agents Based on Quantum Chemistry Calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A
www.nature.com/scientificreports OPEN New information of dopaminergic agents based on quantum chemistry calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A. Ibarra3, Rubicelia Vargas4, Elisabeth Winnberg5 & Ana Martínez6* Dopamine is an important neurotransmitter that plays a key role in a wide range of both locomotive and cognitive functions in humans. Disturbances on the dopaminergic system cause, among others, psychosis, Parkinson’s disease and Huntington’s disease. Antipsychotics are drugs that interact primarily with the dopamine receptors and are thus important for the control of psychosis and related disorders. These drugs function as agonists or antagonists and are classifed as such in the literature. However, there is still much to learn about the underlying mechanism of action of these drugs. The goal of this investigation is to analyze the intrinsic chemical reactivity, more specifcally, the electron donor–acceptor capacity of 217 molecules used as dopaminergic substances, particularly focusing on drugs used to treat psychosis. We analyzed 86 molecules categorized as agonists and 131 molecules classifed as antagonists, applying Density Functional Theory calculations. Results show that most of the agonists are electron donors, as is dopamine, whereas most of the antagonists are electron acceptors. Therefore, a new characterization based on the electron transfer capacity is proposed in this study. This new classifcation can guide the clinical decision‑making process based on the physiopathological knowledge of the dopaminergic diseases. During the second half of the last century, a movement referred to as the third revolution in psychiatry emerged, directly related to the development of new antipsychotic drugs for the treatment of psychosis. -
1 5/17/2018 Nct02118610
5/17/2018 NCT02118610 Treatment of Schizophrenia with l-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist with Anti-inflammatory and Antiprotozoal Activity 1 Abstract Schizophrenia is a devastating and complex illness, with multiple symptom and behavioral manifestations. Antipsychotic medications are the mainstay of treatment; however, many patients only partially respond to treatment. Development of new treatment has not progressed rapidly, in part, because the underlying etiopathophysiology of the illness is not well understood. To date, all pharmacological treatments approved for use in schizophrenia involve primary modulation of the dopamine system. Many agents without dopamine action have failed to demonstrate efficacy. There is growing evidence that schizophrenia may be, in part, due to an inflammatory process and pharmacological treatment approaches that decrease inflammation have shown promise. Thus, treatments that may have anti-inflammatory properties (e.g., TNF-alpha inhibition), but also possess dopamine modulation may prove to be beneficial. This novel medication, l-tetrahydropalmatine (l-THP), has robust anti-inflammatory properties, particularly TNF-alpha and ICAM inhibition; has antiprotozoal activity; and possesses an antipsychotic-like pharmacological profile of D1, D2 and D3 receptor antagonism. The high affinity of l-THP for D1 versus D2 receptors distinguishes it from first generation antipsychotics and its D1 to D2 ratio resembles that of the superior antipsychotic, clozapine. Also, an almost identical compound, l-stepholindine (l-SPD), demonstrates robust antipsychotic activity in humans (both positive and negative symptoms) and is currently used clinically in China. l-THP has been used for over 40 years clinically in China, has a good safety profile to date, and represents a novel and exciting mechanism for schizophrenia treatment. -
( 12 ) United States Patent
US010493080B2 (12 ) United States Patent (10 ) Patent No.: US 10,493,080 B2 Schultz et al. (45 ) Date of Patent : Dec. 3 , 2019 ( 54 ) DIRECTED DIFFERENTIATION OF (56 ) References Cited OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE U.S. PATENT DOCUMENTS 7,301,071 B2 11/2007 Zheng (71 ) Applicants : The Scripps Research Institute , La 7,304,071 B2 12/2007 Cochran et al. Jolla , CA (US ) ; Novartis AG , Basel 9,592,288 B2 3/2017 Schultz et al. 2003/0225072 A1 12/2003 Welsh et al. ( CH ) 2006/0258735 Al 11/2006 Meng et al. 2009/0155207 Al 6/2009 Hariri et al . (72 ) Inventors : Peter Schultz , La Jolla , CA (US ) ; Luke 2010/0189698 A1 7/2010 Willis Lairson , San Diego , CA (US ) ; Vishal 2012/0264719 Al 10/2012 Boulton Deshmukh , La Jolla , CA (US ) ; Costas 2016/0166687 Al 6/2016 Schultz et al. Lyssiotis , Boston , MA (US ) FOREIGN PATENT DOCUMENTS (73 ) Assignees : The Scripps Research Institute , La JP 10-218867 8/1998 Jolla , CA (US ) ; Novartis AG , Basel JP 2008-518896 5/2008 (CH ) JP 2010-533656 A 10/2010 WO 2008/143913 A1 11/2008 WO 2009/068668 Al 6/2009 ( * ) Notice : Subject to any disclaimer , the term of this WO 2009/153291 A1 12/2009 patent is extended or adjusted under 35 WO 2010/075239 Al 7/2010 U.S.C. 154 ( b ) by 0 days . (21 ) Appl. No .: 15 /418,572 OTHER PUBLICATIONS Molin - Holgado et al . “ Regulation of muscarinic receptor function in ( 22 ) Filed : Jan. 27 , 2017 developing oligodendrocytes by agonist exposure ” British Journal of Pharmacology, 2003 , 138 , pp . -
Anti-Infective and Anti-Cancer Properties of the Annona Species: Their Ethnomedicinal Uses, Alkaloid Diversity, and Pharmacological Activities
molecules Review Anti-Infective and Anti-Cancer Properties of the Annona Species: Their Ethnomedicinal Uses, Alkaloid Diversity, and Pharmacological Activities Ari Satia Nugraha 1,2,*, Yuvita Dian Damayanti 1, Phurpa Wangchuk 3 and Paul A. Keller 2,* 1 Drug Utilisation and Discovery Research Group, Faculty of Pharmacy, University of Jember, Jember 68121, Indonesia; [email protected] 2 School of Chemistry & Molecular Bioscience and Molecular Horizons, University of Wollongong, and Illawarra Health & Medical Research Institute, Wollongong, NSW 2533, Australia 3 Centre for Biodiscovery and Molecular Development of Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD 4878, Australia; [email protected] * Correspondence: [email protected] (A.S.N.); [email protected] (P.A.K.); Tel.: +62-331-324-736 (A.S.N.); +61-2-4221-4692 (P.A.K.) Academic Editor: Gianni Sacchetti Received: 8 November 2019; Accepted: 25 November 2019; Published: 3 December 2019 Abstract: Annona species have been a valuable source of anti-infective and anticancer agents. However, only limited evaluations of their alkaloids have been carried out. This review collates and evaluates the biological data from extracts and purified isolates for their anti-infective and anti-cancer activities. An isoquinoline backbone is a major structural alkaloid moiety of the Annona genus, and more than 83 alkaloids have been isolated from this genus alone. Crude extracts of Annona genus are reported with moderate activities against Plasmodium falciparum showing larvicidal activities. However, no pure compounds from the Annona genus were tested against the parasite. The methanol extract of Annona muricata showed apparent antimicrobial activities.